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ABSTRACT
Objective To estimate the cost to the NHS and to parents
and carers of treating febrile preschool children with
paracetamol, ibuprofen, or both, and to compare these
costs with the benefits of each treatment regimen.
Design Cost consequences analysis and cost
effectiveness analysis conducted as part of a three arm,
randomised controlled trial.
Participants Children between the ages of 6 months and
6 years recruited from primary care and the community
with axillary temperatures ≥37.8°C and ≤41°C.
Interventions Paracetamol, ibuprofen, or both drugs.
Main outcomemeasures Costs to the NHS and to parents
and carers. Cost consequences analysis at 48 hours and
5 days comparing cost with children’s temperature,
discomfort, activity, appetite, and sleep; cost
effectiveness analysis at 48 hours comparing cost with
percentage of children “recovered.”
Results Difficulties in recruiting children to the trial
lowered the precision of the estimates of cost and some
outcomes. At 48 hours, cost to the NHS was £11.33 for
paracetamol, £8.49 for ibuprofen, and £8.16 for both
drugs. By day 5 these costs rose to £19.63, £18.36, and
£13.92 respectively. For parents and carers, the 48 hour
costs were £23.86 for paracetamol, £20.60 for ibuprofen,
and £25.07 for both, and the day 5 costs were £26.35,
£29.90, and £24.02 respectively. Outcomes measured at
48 hours and 5 days were inconclusive because of lack of
power; the cost effectiveness analysis at 48 hours
provided little evidence that one treatment choice was
significantly more cost effective than another. At 4 hours
ibuprofen and the combined treatment were superior to
paracetamol in terms of the trial primary outcome of time
without fever; at 24 hours the combined treatment
performed best on this outcome.
Conclusions There is no strong evidence of a difference in
cost between the treatments, but clinical and cost data
together indicate that using both drugs together may be
most cost effective over the course of the illness. This
treatment option performs best and is no more expensive
because of less use of healthcare resources, resulting in
lower costs to the NHS and to parents.
INTRODUCTION
Fever is a common symptom of many childhood
illnesses. Although these are often self limiting, the
fever itself cancausedistress anddiscomfort to thechild
and anxiety to parents. Over the counter preparations
are available to relieve fever and its associated
symptoms; they are used extensively, but the best
treatment remains unclear. European expenditure on
over the counter purchases of paracetamol (acetami-
nophen) for children has fallen between 1997 and 2004
(from £188m to £128m), whereas the use of ibuprofen
has increased during the same period (from £65m to
£277m, personal communication Boots Health Care).
Many parents consult the National Health Service
(NHS) for advice through general practices, walk-in
centres, and NHS Direct. One consequence of this is
widespread prescribing of antipyretics for children; for
example, in 2004 prescriptions for oral suspensions of
paracetamol and ibuprofen cost about £3.5m in
England alone.1 Paracetamol and ibuprofen are
increasingly used together for the relief of fever and
its associated symptoms, though it is not known
whether a combination of both is superior to either
single drug.One study that compared these treatments
collected somedata on resource use, but thesewere not
valued.2 To our knowledge, the cost implications have
not been previously investigated.
The aim of this study was to estimate the cost to the
NHS and to parents and carers of treating preschool
children with a fever with paracetamol, ibuprofen, or
both drugs. These costs were compared with the
benefits of each treatment regimen.
METHODS
This evaluation forms part of a randomised controlled
trial conducted in Bristol, as described in our associated
paper.3 Children between the ages of sixmonths and six
yearswith a temperature of at least 37.8°Candnohigher
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than 41°C were recruited to the study between January
2005 andMay 2007 by one of threemethods. Local and
remote recruitment was from general practices, out of
hours cooperatives, NHS Direct, a walk-in centre, and
the emergency department of a children’s hospital.
Childrenwerealso recruiteddirect fromthecommunity.
Participants were randomised to one of three treatments
options: paracetamol alone, ibuprofen alone, or a
combination of both. Placebo drugs were used to blind
parents and researchers to theallocated treatment.These
drugs were administered regularly for the first 24 hours,
at themaximumdoseappropriate for the child’sweight.3
Between 24 and 48 hours parents gave the drugs as
required, depending on the child’s symptoms.
The primary outcomes of “time without fever” and
discomfort weremeasured in the first four hours and at
48 hours respectively. Additional secondary outcomes
including temperature, activity, appetite, and sleep
were measured at different time points across the five
day follow-up period.
Study design
The economic evaluation was conducted from the
perspectives of the NHS and of parents and carers.We
included all relevant resource use during the five days
after randomisation, excluding the consultation at
which recruitment to the study tookplace, if applicable.
Costs to theNHS includedpracticebasedconsultations
withadoctorornurse, telephoneconsultations, visits to
a walk-in centre, contacts with NHS Direct, out of
hours care, visits to accident and emergency depart-
ments, inpatient hospital care, ambulance use, and
prescribed medication.
For the parents and carers, direct costs included
travel to healthcare facilities for visits associated with
the child’s fever, over the counter drugs purchased,
extra care for dependents required because of the
child’s illness, and loss of earnings as a result of the
child’s illness.We also included a cost representing the
over the counter cost of the study drugs as most
antipyretics in the United Kingdom are bought rather
than prescribed.
Cost consequences analysis
Wecarriedout a cost consequences analysis at 48hours
and fivedays frombaseline for theNHSand forparents
andcarers.Werecordeda rangeofbenefits at both time
points, including the child’s temperature, discomfort,
activity, appetite, and sleep. These were treated as
individual outcomes and also combined to provide an
indication of whether the child had “fully recovered.”
This was based on parents reporting that the child was
“normal” for him or her with respect to discomfort,
activity, appetite, and sleep and on the child having a
temperature <37.2°C. Thus “fully recovered” is in
effect “returned to normal for that child.”
Cost effectiveness analysis
Weused the combinedoutcomeof “fully recovered” in
a cost effectiveness analysis at 48 hours to estimate the
cost per extra child returning to “normal for that child”
and to indicate the relative efficiency of each treatment
at a point before it was anticipated that most children
would have recovered fully.
Data collection and unit costs
Aresearchnurse collecteddata fromparents andcarers
on resourceuse andout of pocket expensesbymeansof
a face to face questionnaire at 48 hours and by
telephone at day 5. Table 1 shows the source of
costingandunit costs.Wevaluedprimarycare contacts
in accordancewithCurtis andNetten,4 andweused the
NHS tariff 5 andDepartment ofHealth reference costs 6
for secondary care and ambulance services.We valued
visits to thewalk-in centre andcontactwithNHSDirect
in accordance with information from published
national evaluations. 78 For prescribed drugs, we used
thecosts reported in theBritishNational Formulary, 9 and
we used the AA schedule of motoring costs10 for
valuing travel by car. Parents who reported loss of
income were asked how many days of work had been
affected, and this was valued using a national wage
rate. 11Wecosted the studydrugs as thoughparentshad
bought them over the counter. Throughout the trial
Table 1 | Resources (and their unit costs) considered in
economic analysis of treating febrile preschool children
with paracetamol, ibuprofen, or both
Resource Unit cost (£)
Primary care4:
General practitioner at surgery 21.00
General practitioner by telephone 23.00
Practice nurse 8.00
Health visitor 24.83
Out of hours15:
Nurse telephone 12.00
Doctor telephone* 34.50
Doctor face to face† 31.50
Walk-in centre7 29.81
NHS Direct8 18.55
Accident and emergency department5 71.00
Inpatient stays5:
Pneumonia 1063.00
Bronchiolitis 942.00
Upper respiratory tract infection 550.00
Ambulance6 132.90
Study drugs‡:
Paracetamol (100 ml) 2.48
Ibuprofen (100 ml) 4.13
Study drugs for sensitivity analysis§:
Paracetamol (100 ml) 0.42
Ibuprofen (100 ml) 2.69
Travel costs (per mile)10 0.49
Lost income per day11 94.80
*Based on a 10 minute consultation.
†Based on a 10.8 minute consultation.
‡Mean cost reported by parents buying these over the counter between
48 hours and five days after baseline.
§Cost if prescribed (from British National Formulary9).
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children received doses of study medicines according
to their weight. We costed the consumption of
medicines accordingly. All resources were valued in
pounds sterling at 2006 prices using an appropriate
inflation index.4
Data analysis
We estimated frequencies of resource use by the
patients in each treatment arm, and mean cost per
patient in each arm. We excluded inpatient care and
use of ambulances in the base case analysis as these are
Table 2 | Resource use associatedwith treating febrile preschool childrenwith paracetamol, ibuprofen, or both. Values aremean (SD) use per episode per child
for five day follow-up
Item of resource use
Paracetamol Ibuprofen Paracetamol + ibuprofen
n Mean (SD) n Mean (SD) n Mean (SD)
Primary care consultations at surgery 51 0.24 (0.51) 50 0.30 (0.51) 52 0.42 (0.61)
Primary care telephone consultations 52 0.08 (0.27) 50 0.06 (0.24) 52 0.04 (0.19)
Out of hours consultations 52 0.15 (0.50) 50 0.10 (0.10) 52 0.06 (0.31)
Other primary care consultations 52 0.19 (0.19) 50 — 52 0.04 (0.20)
Prescribed drugs (No of items) 52 0.27 (0.56) 50 0.24 (0.52) 52 0.19 (0.44)
Over the counter drugs (No of items):
Excluding study drugs 52 0.44 (0.73) 50 0.36 (0.63) 52 0.52 (0.85)
Including study drugs 52 1.19 (0.40) 50 1.16 (0.37) 52 2.08 (0.27)
A&E visits 51 0.04 (0.20) 50 0.10 (0.42) 52 0.04 (0.19)
Inpatient hospital stays (No of nights) 51 0.02 (0.14) 49 0.12 (0.60) 52 0.08 (0.56)
Ambulance use (No of journeys) 51 — 50 0.06 (0.31) 52 0.02 (0.14)
Days off work (No of days) 52 0.60 (1.12) 49 0.77 (1.44) 52 0.44 (0.80)
Loss of income (proportion of parents incurring a cost) 52 0.10 (0.30) 52 0.19 (0.40) 52 0.12 (0.32)
Childcare cost (proportion of parents incurring a cost) 52 0.04 (0.19) 52 0.08 (0.27) 52 0.06 (0.24)
n=Number of patients included in analysis. A&E=Accident and emergency department.
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Fig 1 | Cost effectiveness planes comparing cost of treating fever in preschool children with the proportion of children who have
returned to “normal for that child” at 48 hours
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unusual in a primary care population and could be
unequally distributed by chance. Bootstrapping (1000
replicates) was used to estimate cost effectiveness
planes and cost effectiveness acceptability curves to
indicate the level of uncertainty around the point
estimates of the incremental cost effectiveness ratios.
It was not necessary to discount the costs and
outcomes, as the time horizon of the study was five
days. All analyses were carried out with Microsoft
Excel and Stata 9.
Sensitivity analysis
We tested the robustness of our results against three
possible areas of subjectivity. Firstly, we re-estimated
the cost per patient from both perspectives if the study
drugs had been prescribed rather than purchased over
the counter. Secondly, we investigated the effect on the
results if dosing had been by age rather than weight.
Thirdly, we estimated the cost of hospitalisations.
RESULTS
A total of 156 children were recruited to the study—45
(29%) through local recruitment, 84 (54%) by the
remote method, and 27 (17%) directly from the
community. Of the 52 children in each of the three
treatmentgroups, those in the combined treatment arm
were slightly younger and weighed less than the others
(mean age 25.1 months v 28.7 months for the
paracetamol only group and 28.1 months for the
ibuprofen only group; mean weight 12.6 kg v 13.0 kg
and 13.4 kg respectively). There were more boys than
girls (87 v 69), and this imbalance was most concen-
trated in the ibuprofen only group (37 (71%) boys).
Most (64%) had a non-specific viral illness or a
respiratory tract infection, 16% had otitis media, and
the remaining 20% were assigned a variety of other
diagnoses.
Data on NHS costs were complete for 154 (99%)
children at 48 hours and 150 (96%) at five days.
Personal costswere reportedby143 (92%)parents at 48
hours and 130 (83%) at day 5.
Resource use
Table 2 shows themean resource use per child over the
five day follow-up. Sixty per cent of children (93) used
no extra NHS resources after the consultation at which
they were recruited to the study and 71% (109) had no
contact with their general practitioner. Most (52%)
primary care contacts were face to face at the surgery,
14 (16%)werewith theout of hours service, and the rest
were either telephone consultations or with a variety of
other primary care providers such aswalk-in centres or
NHS Direct. Children receiving paracetamol had
fewest face to face consultations, though most con-
sultations overall, but there was no significant differ-
ence in total use of primary care resources among the
three groups.
Thirty six prescriptions were issued (excluding two
for drugs that had been provided in the study). Most
(81%) were for antibiotics. Of the 113 over the counter
preparations that were purchased (for 46 children), 62
(55%)were for paracetamol or ibuprofen, and 29 (47%)
of these were bought in the first 48 hours (when study
drugs were provided) and 24 (83%) were for the active
ingredient being provided.
Five children spent some time inhospital.Ninety two
daysofworkwere lost among48 (31%)parents because
of their child’s illness, and 21 (44%) of these reported a
direct loss of earnings. Nine (6%) parents incurred out
of pocket expenses for sibling or other dependent care
because of the child’s illness.
Cost analysis
Table 3 shows the mean cost per patient, by treatment
group, during the first 48 hours and over the five day
Table 3 | Costs (£) associatedwith treating febrile preschool childrenwith paracetamol, ibuprofen, or both. Values aremean
(SD) cost per child by treatment group
Cost item
0-48 hours (intervention period) 0-5 days (total follow-up)
Paracetamol Ibuprofen
Paracetamol +
ibuprofen Paracetamol Ibuprofen
Paracetamol +
ibuprofen
NHS costs (n=51) (n=52) (n=51) (n=50) (n=49) (n=51)
Primary care doctor consultations 6.15 (15.41) 3.99 (10.67) 6.48 (13.36) 12.10 (28.30) 10.38 (18.17) 10.23 (14.67)
Primary care nurse consultations 0 0.15 (1.11) 0 0.58 (4.09) 0.16 (1.14) 0
Other primary care consultations 2.03 (7.29) 0 0 3.55 (9.37) 0 0.36 (2.60)
Total primary care cost 8.18 (17.26) 4.14 (11.16) 6.48 (13.36) 16.23 (34.11) 10.54 (18.42) 10.59 (15.16)
A&E 2.78 (13.92) 4.10 (21.84) 1.39 (9.94) 2.84 (14.05) 7.24 (29.86) 2.78 (13.92)
Prescribed drugs 0.37 (1.00) 0.25 (0.85) 0.29 (0.86) 0.56 (1.27) 0.58 (1.43) 0.55 (1.63)
Total NHS cost 11.33 (23.18) 8.49 (29.13) 8.16 (16.36) 19.63 (38.11) 18.36 (40.26) 13.92 (23.17)
Parental costs (n=47) (n=49) (n=47) (n=45) (n=42) (n=43)
Travel cost 0.31 (1.04) 0.02 (0.08) 0.21 (0.74) 0.70 (1.56) 0.29 (0.77) 0.35 (0.89)
Over the counter drugs* 2.52 (0.29) 4.13 (0.00) 6.75 (0.68) 3.69 (1.61) 4.74 (1.44) 7.96 (2.29)
Other expenditure 21.03 (62.18) 16.44 (58.50) 18.10 (51.64) 21.97 (63.41) 24.83 (90.81) 15.64 (46.74)
Total parental costs 23.86 (62.20) 20.60 (58.52) 25.07 (51.60) 26.35 (63.37) 29.90 (90.68) 24.02 (46.36)
A&E=Accident and emergency department.
*Includes cost of study drugs as if parents had bought over the counter.
RESEARCH
page 4 of 8 BMJ | ONLINE FIRST | bmj.com
follow-up. About 60% of all NHS costs are accounted
for by general practitioner appointments, and visits to
accident and emergency departments was the second
largest contributor. Personal costs were dominated by
loss of income.
Cost consequences analysis: 48 hours and 5 days
Table 4 shows the cost consequencesmatrix. From the
perspective of the NHS, the combined drug treatment
was cheapest at both 48 hours and 5 days. Paracetamol
only was the most expensive. Ibuprofen only was
cheapest to parents at 48 hours, but by day 5 the
combined treatment had become less expensive
because the greater parental spending on drugs was
offset by lower travel costs (because of less health
service use) and less time off work.
The results for the children’s temperature, discomfort,
activity, appetite, and sleep suggest that ibuprofen alone
may perform best at 48 hours, but the wide confidence
intervals around all incremental costs and outcomes
indicateonlyweakevidence insupportofanydifferences.
Cost effectiveness analysis at 48 hours
Table 5 presents the incremental costs and benefits at
48 hours. Cost is expressed as incremental mean cost
per child by treatment group; benefits are expressed as
the proportion of children per group returning to
normal. From the NHS perspective, the combined
treatment is cheaper but (slightly) less effective than
either of the two monotherapies, paracetamol alone is
more expensive and marginally more effective than
ibuprofen alone.
From the parental perspective, paracetamol and
ibuprofen together ismore expensive and less effective
than either of the single treatments. Ibuprofen alone is
cheaper but less effective than paracetamol alone. The
level of uncertainty around the incremental cost
effectiveness ratios is shown by the bootstrapped
replications shown on the cost effectiveness planes in
fig 1. Replications fall in all four quadrants for all
comparisons, suggesting there is little evidence that any
treatment choice is significantly more cost effective
than any other. This is reinforced by the cost
effectiveness acceptability curves in fig 2, where none
of the probabilities of one treatment being more cost
effective than another reaches 50%.
Sensitivity analysis
Table 6 gives the results of the three sensitivity analyses
for different scenarios. For each one-way analysis, we
show the mean (SD) cost for the NHS and for parents
basedon the revisedassumptions.Wealsogive thenew
incremental cost and the change in the incremental cost
from the base case results. Firstly, if the study drugs
were prescribed rather than bought over the counter,
costs to theNHS increasebutby less than theassociated
decrease in parental costs. The increase inNHS costs is
greatest for the combined treatment, though this is still
the cheapest treatment option for the NHS at day 5.
Secondly, if parentsdosed their childbyage (asper the
instructionson thebottle) rather thanbyweight (as in this
study) then the parents of 45 children (29%) would have
used fewer bottles of medicine. Although about half
(51%) of these children were in the paracetamol only
group, the cost impact is greatest in the combined
treatmentgroupbecause twodrugshave tobepurchased
and ibuprofen is more expensive than paracetamol.
Finally, we included secondary care costs (inpatient
care, ambulance use, and travel cost for families). These
are estimated at day 5 only as the episodes of care
generally spanned thewhole period.Of the five children
who received secondary care, one was in the para-
cetamol only group, one in the combined treatment
group, and three were in the ibuprofen only group. This
Table 4 | Cost consequences analysis associatedwith treating 156 febrile preschool childrenwith paracetamol, ibuprofen, or both
Costs and outcomes
0-48 hours (intervention period) 0-5 days (total follow-up)
Paracetamol +
ibuprofen v
paracetamol
Paracetamol +
ibuprofen v
ibuprofen
Ibuprofen v
paracetamol
Paracetamol +
ibuprofen v
paracetamol
Paracetamol +
ibuprofen v
ibuprofen
Ibuprofen v
paracetamol
Incremental mean (95% CI) cost per patient (£)
NHS costs −3.16 (−11.0 to 4.7) −0.33 (−9.6 to 8.9) −2.84 (−13.1 to 7.5) −5.71 (−18.1 to 6.7) −4.44 (−17.4 to 8.5) −1.27 (−16.9 to 14.4)
Parental costs 1.20 (−22.2 to 24.6) 4.47 (−17.9 to 26.9) −3.27 (−27.7 to 21.2) −2.33 (−26.0 to 21.3) −5.88 (−36.8 to 25.1) 3.55 (−29.6 to 36.7)
Outcomes*
Temperature (°C): adjusted
difference (95% CI) between means
0.21 (−0.20 to 0.61) 0.23 (−0.18 to 0.64) −0.02 (−0.46 to 0.41) −0.14 (−0.51 to 0.22) −0.08 (−0.45 to 0.28) −0.06 (−0.45 to 0.34)
Discomfort: odds ratio (95% CI) of
“well” v “unwell”
1.33 (0.49 to 3.56) 0.89 (0.32 to 2.43) 1.50 (0.53 to 4.26) 0.45 (0.13 to 1.59) 0.75 (0.24 to 2.34) 0.60 (0.15 to 2.39)
Activity: odds ratio (95% CI) of “well/
normal” v “unwell/not normal”
0.67 (0.26 to 1.70) 0.40 (0.13 to 1.20) 1.68 (0.60 to 4.67) 0.30 (0.08 to 1.10) 0.45 (0.14 to 1.49) 0.66 (0.15 to 2.99)
Appetite: odds ratio (95% CI) of
“well/normal” v “unwell/not normal”
1.08 (0.41 to 2.84) 0.80 (0.30 to 2.01) 1.39 (0.50 to 3.82) 1.16 (0.45 to 2.94) 1.07 (0.42 to 2.73) 1.10 (0.40 to 2.91)
Sleep: odds ratio (95% CI) of “well/
normal” v “unwell/not normal”
0.84 (0.34 to 2.07) 0.56 (0.22 to 1.40) 1.49 (0.57 to 3.92) 0.64 (0.25 to 1.62) 1.09 (0.44 to 2.71) 0.59 (0.17 to 1.35)
Difference (95% CI) in proportion of
children returning to “normal for that
child”
−0.06 (−0.23 to 0.11) −0.04 (−0.22 to 0.13) −0.02 (−0.20 to 0.16) −0.04 (−0.23 to 0.15) 0.04 (−0.15 to 0.23) −0.08 (−0.27 to 0.11)
*Adjusted for minimisation variables: age, temperature, fever duration, antibiotic use and discomfort.
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is reflected in the cost estimates, which increase by about
£20per hospitalised childper group (that is, about £1000
per hospitalisation). There is no evidence that any of
these events was related to the study drugs the child
received, and the combined treatment remains themost
attractive choice for the NHS and for parents.
DISCUSSION
Over the course of five days themean cost of care for a
preschool child with fever was estimated to be £27 to
parents and carers and £17 to the NHS, excluding the
cost of any index consultation. Two thirds of the NHS
costs were due to consultations with general practi-
tioners. Taken together, the results of our present study
and those reported in our trial paper2 suggest that
paracetamol and ibuprofen given in combination is
more effective at 24 hours than either drug given alone
and possibly cheaper over a five day period.
Strengths and weaknesses of the study
To our knowledge, this is the first investigation of the
cost effectivenessofdual antipyreticdrugsversus single
drug use. This economic evaluation benefited from
being part of a randomised controlled trial. Data
collection and entry were thorough and rigorously
checked; anddataqualitywas enhancedbyourmethod
of collection: the research nurses spoke to parents face
to faceorby telephone.For the samereason, the level of
missing data was minimal.
We are aware of several limitations. Because of
recruitment problems, we were unable to achieve our
original target sample size.2This affected interpretation
of the cost data, and some of the outcome data as the
study was eventually powered to detect clinical
differences solely in the time spent without fever.
This outcome was measured at 4 hours and 24 hours,
but cost data were not collected for this short time
period. We were underpowered with respect to the
outcomes measured or reported at 48 hours and five
days, when cost data were collected.
The cost effectiveness analysis at 48 hours was based
on a combined measure of child’s temperature,
discomfort, activity, appetite, and sleep—from which
we defined “recovered” to mean “normal for that
child.” As these outcomes were affected by the lack of
power, our choice of outcome for the cost effectiveness
analysis limits its value. None of the comparisons
showedevidenceof differencesbetween the treatments
Pr
ob
ab
il
it
y 
th
at
 in
te
rv
en
ti
on
 is
 c
os
t
ef
fe
ct
iv
e 
co
m
pa
re
d 
w
it
h 
th
e 
co
m
pa
ra
to
r
0
0.2
0.4
Cost per extra child returned to “normal for that child” (£)
Cost effectiveness from parent perpective
Cost effectiveness from NHS perpective
Pr
ob
ab
il
it
y 
th
at
 in
te
rv
en
ti
on
 is
 c
os
t
ef
fe
ct
iv
e 
co
m
pa
re
d 
w
it
h 
th
e 
co
m
pa
ra
to
r
0 100 200 300 400 500 600 700
0
0.2
0.4
0.1
0.3
0.5
0.1
0.3
0.5
Paracetamol v ibuprofen
Paracetamol + ibuprofen v ibuprofen
Paracetamol + ibuprofen v paracetamol
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Table 5 | Cost effectiveness at 48 hours for treating febrile preschool childrenwith paracetamol, ibuprofen, or both
Paracetamol Ibuprofen
Paracetamol +
ibuprofen
Paracetamol + ibuprofen
v paracetamol
Paracetamol +
ibuprofen v ibuprofen Ibuprofen v paracetamol
NHS perspective (n=154)
Mean (SD) total cost (£) 11.33 (23.18) 8.49 (29.13) 8.16 (16.36) — — —
Incremental cost (95% CI) (£) — — — −3.16 (−11.05 to 4.72) −0.33 (−9.59 to 8.93) −2.84 (−13.14 to 7.46)
Proportion (SD) of children
recovering*†
0.27 (0.45) 0.27 (0.45) 0.24 (0.43) — — —
Incremental benefit (95% CI) — — — −0.04 (−0.21 to 0.13) −0.03 (−0.21 to 0.14) −0.01 (−0.18 to 0.17)
Cost per extra child
recovering†
— — — £80.70 £9.62 £537.65
Parent perspective (n=143)
Mean (SD) total cost (£) 23.86 (62.20) 20.60 (58.52) 25.07 (51.60) — — —
Incremental cost (95% CI) (£) — — — 1.20 (−22.20 to 24.60) 4.47 (−17.90 to 26.90) −3.27 (−27.70 to 21.20)
Proportion (SD) of children
recovering†
0.30 (0.46) 0.29 (0.46) 0.23 (0.43) — — —
Incremental benefit (95% CI) — — — −0.06 (−0.25 to 0.12) −0.05 (−0.23 to 0.13) −0.01 (−0.20 to 0.17)
Cost per extra child
recovering†
— — — £−18.87 £−86.55 £268.78
*Based on complete cases: proportions vary by perspective due to missing data.
†Recovering is defined as “returning to normal for that child.”
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in terms of cost effectiveness, and it is therefore difficult
to draw strong conclusions from this part of the
analysis.
The economic evaluation was intended to enhance
the associated clinical study3 by taking a longer term
view and provide information about costs and benefits
over the whole episode of illness. We chose a five day
follow-up period because we expected that most
children would have recovered by this time. In fact,
this was not the case; according to our strict definition,
only 36% of children had recovered by five days,
mainly because their appetite and sleep had not
returned to normal. Eating and sleeping patterns
seem to remain disrupted after an illness for longer
than we originally hypothesised, but it is unlikely that
these effects would result in significant further use of
healthcare resources as nearly 90% children had a
normal temperature and no discomfort at this point. A
further, related, limitation is lack of evidence about any
long termadverse effects and allied costs of using either
or both antipyretic drugs for childhood fever.
These limitations show the value of presenting a cost
consequences matrix of disaggregated results, which
may bemore valuable when different perspectives and
different outcomes are of interest to different stake-
holders. Although the results presented here can only
be indicativebecauseof the lackofpower, theyendorse
our clinical findings.3
Finally, although we were able to estimate the direct
cost to parents of time off work, we were not able to
estimate the monetary value to society of that lost
productivity. Such valuations are contentious and
particularly so in a case such as thiswhen the individual
time off work is small but the total at a population level
could be considerable. The true cost of this childhood
illness is therefore likely to be greater than estimated
here.
Comparison with other literature
Our results are similar to those of Sarrell et al, who
reported lower resource use in children receiving
paracetamol and ibuprofen together compared with
those receiving either drug on its own.2We have found
no published economic evaluations comparing single
and dual treatment for childhood fever, though we can
assess the face validity of the results of our economic
analysis by looking at the cost of illness. In this study,
themean cost of an episode of illness over five dayswas
£38 to the NHS (allowing for the cost of the initial
consultation), and £27 to parents and carers. A recent
cost of illness analysis estimated the cost of an episode
of childhood cough to be £25 to the NHS and £15 to
parents.12 Fever resulted in greater use of healthcare
resources across the board, the difference being most
marked in the use of accident and emergency depart-
ments, out of hours care, the purchase of over the
counter drugs, and the effect on parental time off work.
Meaning of the study
This economic evaluation adds to the findings of our
clinical study by providing information on the relative
cost of the alternative treatments over a longer time
period. The results show that, over the course of the
whole illness, treating children with both drugs may
lead to less use of other healthcare resources than does
either of the drugs alone. This would result in lower
costs to the NHS and to parents because of less travel
and time off work.
Table 6 | Sensitivity analyses for different scenarios on costs associatedwith treating febrile preschool childrenwith paracetamol, ibuprofen, or both
Different scenarios
Mean (SD) costs Incremental cost (change from base case)
Paracetamol Ibuprofen
Paracetamol +
ibuprofen
Paracetamol +
ibuprofen v
paracetamol
Paracetamol +
ibuprofen v ibuprofen
Ibuprofen v
paracetamol
If study medicines had been prescribed
For 0-48 hours:
NHS costs 11.69 (22.98) 11.18 (29.13) 11.27 (16.36) −0.42 (2.74) 0.09 (0.42) −0.52 (2.32)
Parental costs 21.88 (62.09) 16.87 (59.89) 19.30 (51.39) −2.58 (−3.78) 2.43 (−2.04) −5.01 (−1.74)
For 0-5 days:
NHS costs 20.00 (37.99) 20.92 (39.87) 17.02 (23.18) −2.98 (2.73) −3.91 (0.53) 0.92 (2.20)
Parental costs 22.88 (63.27) 25.28 (90.81) 16.14 (46.68) −6.73 (−4.13) −9.14 (−2.48) 2.40 (−1.65)
If dose by age
Parental costs for 0-5 days 25.36 (63.27) 29.41 (90.81) 22.75 (46.68) −2.60 (−0.28) −6.66 (−0.78) 4.05 (0.50)
Including secondary care costs
NHS costs for 0-5 days 40.89 (164.8) 78.64 (268.3) 35.19 (168.6) −5.70 (0.01) −43.45 (−39.01) 37.75 (39.02)
Parental costs for 0-5 days 26.89 (63.23) 31.21 (90.6) 24.28 (46.3) −2.60 (−0.27) −6.92 (−0.26) 4.32 (0.30)
WHAT IS ALREADY KNOWN ON THIS TOPIC
Fever is a common symptom of many childhood illnesses
Paracetamol and ibuprofen are often used, separately or together, to reduce temperature and
relieve symptoms, but the optimal treatment regimen in termsof cost andoutcomes isunclear
WHAT THIS STUDY ADDS
Cost of care of children with a fever is largely borne by parents and the primary care sector
Over the courseof fivedays, using paracetamol and ibuprofen togethermay lead to lessuse of
healthcare resources than either drug alone, making the combined treatment the best value
option
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Bothparacetamol and ibuprofen are relatively cheap
drugs, but fever is commonamongyoungchildren, and
the population effect of using the most appropriate
treatment could be substantial. About 70% of pre-
school children have a fever each year,13 and profes-
sional help is sought for about 60%of them, resulting in
over 1.5 million consultations.14 Hence even a small
reduction in cost per case could have a large impact on
overall budgets. The results of this study provide some
guidance on the preferred treatment for preschool
children with a fever. This could produce substantial
savings in the current cost burden, which mainly falls
on primary care and parents. Furthermore, reducing
uncertainty about the optimal treatment lessens the
need forparents to consult their general practitioner for
advice, thus generating further savings.
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